title: [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].
abstract: Lung cancer is the leading cause of cancer-related death. Targeting the vascular endothelial growth factor (VEGF) pathways in combination with standard chemotherapy can improve response rate and survival in non-small cell lung cancer. Since October 2006, a new class of drugs targeting angiogenesis has been introduced for the treatment of advanced lung cancer. Bevacizumab, an antibody directly targeting VEGF was the first agent to be approved. Other small molecule tyrosine kinase inhibitors targeting the VEGF receptor are also active in the treatment of advanced lung cancer and are currently under development. Most of these new drugs are well tolerated though potentially significant toxicities such as haemoptysis and hypertension have been observed. This article will review these new-targeted anti-angiogenic agents with a focus on their use in lung cancer and on their important side effects.
authors.affiliation: Service de pneumologie, CHU de Nancy, allée du Morvan, Vandœuvre-lès-Nancy, France. christelle.clementduchene@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Clément-Duchêne
authors.forename: B
authors.initials: B
authors.lastname: Godbert
authors.forename: Y
authors.initials: Y
authors.lastname: Martinet
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab